BURLINGAME, Calif.--(BUSINESS WIRE)-- Urigen N.A., Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders, has successfully completed its shareholder meeting with Urigen’s shareholders approving the merger with Valentis, Inc.
